Genetic signature of breast cancer with lymphangitic spread to the chest wall: Results from a randomized phase II study combining bevacizumab with oral vinorelbine plus capecitabine (BEVIX)

Autor:	Franco Nolè, Marzia Locatelli, Francesco Bertolini, Giulia Viale, A. Goldhirsch, Luca Fumagalli, Giuseppe Curigliano, S. Giudici, Viviana Galimberti, M. Alkalay
Rok vydání:	2010
Předmět:	Oncology Cancer Research medicine.medical_specialty Bevacizumab business.industry Phases of clinical research medicine.disease Vinorelbine Gene expression profiling Capecitabine Basal (phylogenetics) Breast cancer Internal medicine Cohort medicine business medicine.drug
Zdroj:	Journal of Clinical Oncology. 28:1078-1078
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2010.28.15_suppl.1078
Popis:	1078 Background: No surrogate biomarkers have been identified to predict response to an antiangiogenic agent for cancer treatment. Methods: We collected basal tissue samples from patients with lymphangitic spread to the chest wall with or without metastases, treated with bevacizumab in combination with sequential, and/or concurrent oral vinorelbine plus capecitabine. Gene expression profiling was performed using Affymetrix HG-U133 Plus 2.0 arrays. Data were analyzed using Partek Genomic Suite 6.4 and GeneSpring 7.0. Normal breast tissue was used as control. Results: Out of 46 planned, 45 patients have been enrolled. The data here reported are related to 20 patients included in the concurrent treatment arm. We observed 8 PR (40%) and 11 SD (55%). Global gene expression was analyzed in tumor samples from 18 patients bearing a triple negative phenotype. Compared with normal breast samples and breast tumors of other subtypes, this cohort displayed a specific gene expression profile, similar to that described ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8aafb3457299e542cc6dd11c1ada2578 https://doi.org/10.1200/jco.2010.28.15_suppl.1078 Zobrazit plný text záznamu